Replies to post #110641 on Biotech Values

[Jonathan Robinson]

If nothing happens in another three months, I’ll reduce this number to $50M, and if nothing happens in another six months, I’ll say that the value is zero. JMHO, FWIW

Ahhhhhh, you are exactly (almost) matching the quarterly cash increases as long as sole generic status is maintained for Lovenox.

Jon

[DewDiligence]

Update on M118 valuation: In #msg-57621347, posted on 12/10/10, I said:

…from the valuation table in #msg-54022252, I ascribed only $150M of value to the M118 program when that post was written [in Sep 2010]. Since M118 has not advanced at all since then, I would say that the program value has now dropped to $100M. If nothing happens in another three months, I’ll reduce this number to $50M, and if nothing happens in another six months, I’ll say that the value is zero.

Another six months (nine months in all) have now elapsed so, as promised, I am lowering the value of M118 in my model to zero. Please see the next post for an updated valuation table for MNTA’s non-Lovenox assets.